ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SHR 3201

A development code. Also written as “SHR 3201 Injection”.

Its studies are mostly in Alzheimer Disease, led by Jiangsu HengRui Medicine.

Furthest: phase 1, since Oct 16, 20261 company-led study, 1 open or runningNext primary completion: Jan 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine11 open or runningphase 1since Oct 16, 2026Oct 16, 2026Jan 2027phase 1 · NCT07889349

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2026First study: phase 1 study in Alzheimer DiseaseFirst studyNCT07889349 · 50 planned · China

Ahead

  1. Jan 2027Primary completion: phase 1 study in Alzheimer DiseaseNCT07889349

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07889349Alzheimer Disease · China1RecruitingJan 202750

How it is read

Names in the registry

  • “SHR 3201 Injection”, 1 entry

Codes read as this program: SHR3201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.